Celldex Therapeutics, Inc. is 1.5x more valuable than Anbio Biotechnology by market capitalization ($2.30 B vs $1.50 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CLDX | NNNN |
|---|---|---|
| Market cap | $2.30 B | $1.50 B |
| US-listed rank | #1998 | #2317 |
| Revenue (latest FY) | $1.54M | $8.65M |
| Net income (latest FY) | -$258.76M | $6.40M |
| Net margin | -16748.0% | 74.1% |
| P/E (trailing FY) | - | 234.2 |
| SEC filings | 1,268 | 40 |
Celldex Therapeutics, Inc. is 1.5x more valuable than Anbio Biotechnology by market capitalization ($2.30 B vs $1.50 B).
In their latest fiscal years, Celldex Therapeutics, Inc. reported $1.54M in revenue while Anbio Biotechnology reported $8.65M.
Full pages: Celldex Therapeutics, Inc. and Anbio Biotechnology, or browse the full rankings.